Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
Predicting the Quality of Response to Specific Treatments (PQRST)
Fred Hutchinson Cancer Center
300 participants
Jun 29, 2020
OBSERVATIONAL
Conditions
Summary
This trial collects clinical data and blood samples to predict the quality of response to specific treatments in patients with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy. Collecting and analyzing clinical data and blood samples from patients with cGVHD before and after treatment initiation may help doctors identify changes that may predict treatment response.
Eligibility
Inclusion Criteria5
- Adults age 18 or older
- Prior allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
- No evidence of persistent or progressive malignancy at the time of enrollment
- Agrees to be evaluated at the transplant center before a new line of treatment is started (may be concurrent with the enrollment visit), and later between 2-6 weeks, 3 months and 6 months after index treatment is started or if an additional new therapy is started before 6 months
- Signed, informed consent
Exclusion Criteria3
- Inability to comply with study procedures
- Uncontrolled psychiatric disorder
- Anticipated survival < 6 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Undergo collection of blood sample
Review of medical chart
Ancillary studies
Complete questionnaire
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04431479